Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $133,494.66 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,666 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $8.01, for a total transaction of $133,494.66. Following the transaction, the insider owned 1,144,462 shares in the company, valued at $9,167,140.62. The trade was a 1.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Wednesday, July 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.03, for a total transaction of $133,827.98.
• On Monday, June 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $6.06, for a total value of $101,002.02.

Xeris Biopharma Price Performance

Shares of NASDAQ:XERS traded up $0.06 during trading on Tuesday, hitting $8.19. 1,838,477 shares of the stock were exchanged, compared to its average volume of 1,872,077. The company has a market cap of $1.41 billion, a PE ratio of 136.50 and a beta of 0.66. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. The company has a fifty day moving average price of $7.55 and a two-hundred day moving average price of $6.78. Xeris Biopharma Holdings, Inc. has a 12-month low of $5.25 and a 12-month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. The firm had revenue of $83.13 million during the quarter, compared to the consensus estimate of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. On average, analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Institutional Investors Weigh In On Xeris Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of XERS. Kestra Advisory Services LLC purchased a new position in Xeris Biopharma during the fourth quarter worth $25,000. KBC Group NV acquired a new position in Xeris Biopharma in the 1st quarter valued at about $27,000. Caitong International Asset Management Co. Ltd lifted its holdings in Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after purchasing an additional 7,421 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after purchasing an additional 1,820 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in shares of Xeris Biopharma by 179.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after purchasing an additional 5,000 shares during the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $10.80.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.